StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

No gross margin figures for Keros Therapeutics

Keros Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Keros Therapeutics figures

See a number that looks wrong?